University of Pennsylvania

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Eyenovia, Betaliq Will Have Combined C

With a growing number of complex cell and gene therapies approved globally, mostly for rare disease populations, manufacturers are looking at how to make these products more accessible by delivering a

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re

Plenty of biopharmaceutical firms continue to struggle to raise fresh capital under current financial market conditions with drug developer valuations still well below what they were a few years ago a